Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ALPG | P10696 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434696 | 0.84 | ESR1 (0.58) | FFAR1KMT2AALDH1A1 | |
| SCHEMBL8700030 | 0.83 | KMT2A (0.67) | FFAR1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1343883 | 0.83 | FFAR1 (0.51) | FFAR1KMT2A | |
| SCHEMBL27862777 | 0.83 | FFAR1 (0.51) | FFAR1KMT2A | |
| SCHEMBL9556420 | 0.83 | FFAR1 (0.51) | FFAR1KMT2A | |
| SCHEMBL18382535 | 0.82 | FFAR1 (0.60) | FFAR1KMT2ALMNA | |
| SCHEMBL17144644 | 0.82 | FFAR1 (0.44) | FFAR1KMT2AALDH1A1 | |
| SCHEMBL10260682 | 0.82 | FFAR1 (0.62) | FFAR1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL20408613 | 0.82 | FFAR1 (0.60) | FFAR1KMT2ALMNA | |
| SCHEMBL7831088 | 0.81 | FFAR1 (0.49) | FFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007136325-A1 | 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 2 | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136326-A2 | ) T E TEXT AS EEN ESTA S E Y T S UT O TY TO REA AS O OWS: 1- [ (4- [BENZOYL (METHYL) AMINO] -3- (PHENYL) BUTYL] AZETIDINE DERIVATIVES FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS 3 | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270400-A1 | New compounds 303 | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270399-A1 | New compounds 302 | ALBIREO AB (SE) | 2007-11-22 | — | — | US | disclosed |
| EP-0271225-B1 | INDENE DERIVATIVES AND METHODS | H. LUNDBECK A/S (DK) | 1993-10-13 | — | — | EP | disclosed |
| US-4873344-A | Cyano containing indene derivatives | H. LUNDBECK A/S (DK) | 1989-10-10 | — | — | US | disclosed |
| EP-0271225-A2 | Indene derivatives and methods | H. LUNDBECK A/S (DK) | 1988-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270400-A1 | New compounds 303 | CYP11B2, CYP11B1, SDHA | FFAR1 2759/4885KMT2A 4148/4885LMNA 2492/4885 |
| US-20070270399-A1 | New compounds 302 | CYP11B2, CYP11B1, CYP4B1 | FFAR1 2456/4885KMT2A 3852/4885LMNA 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.